№ files_lp_3_process_9_32409
File format: docx Character count: 11903 File size: 25 KB
Federal administrative supporting statement outlining the statutory authority, implementation framework, eligibility criteria, and information collection process for beneficiary enrollment in the Medicare Part B IVIG Demonstration project.
Program: Medicare IVIG Demonstration
Administering Agency: Centers for Medicare & Medicaid Services (CMS)
Country: United States
Legal Basis: Medicare IVIG Access and Strengthening Medicare and Repaying Taxpayers Act of 2012
Extended Under: Disaster Tax Relief and Airport and Airway Extension Act of 2017
Further Extension: Consolidated Appropriations Act, 2021
OMB Control Number: 0938-1246
CMS Form Number: CMS-10518
Subject: Application for beneficiary participation in the IVIG Demonstration
Target Population: Medicare Part B beneficiaries with primary immune deficiency disease (PIDD)
Enrollment Cap: 6,500 beneficiaries (originally 4,000)
Funding Limit: $45 million including administrative and evaluation costs
Coverage Scope: Bundled payment for medically necessary supplies and services for in-home IVIG administration
Application Requirement: Mandatory signed application by beneficiary and provider
Submission Methods: Mail or fax
Languages Available: English and Spanish
Period of Demonstration: Through December 31, 2023 or until statutory limits are met
Participation Status: Voluntary; may be terminated by beneficiary at any time
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.

Don’t have cryptocurrency yet?

You can still complete your purchase in a few minutes:
  1. Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
  2. In the app, tap Send.
  3. Select network, paste our wallet address.
  4. Send the exact amount shown above.
After sending, paste your TXID (transaction ID) and your email to receive the download link. Need help? Contact support and we’ll guide you step by step.

The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
Issuing Rh Immune Globulin (RhIG)
Year: 2021
Region / city: Canada
Topic: Rh Immunization Prevention
Document Type: Guidelines
Organization / Institution: CSTM
Author: Not specified
Target audience: Healthcare professionals (Physicians, Midwives, Technologists)
Period of validity: Ongoing
Approval date: 2021
Revision date: July 15, 2021
Changes date: August 8, 2014
Rh Immune Globulin Prophylaxis and Testing Requirements According to AABB 29th Standards
Standard: AABB 29th Standards 5.30
Thema: Rh Immune Globulin prophylaxis
Dokumenttyp: Transfusionsrichtlinie
Fachbereich: Transfusionsmedizin
Betroffene Patientengruppe: Rh negative Patientinnen und Patienten
Zielgruppe: Schwangere Frauen und transfusionsmedizinische Dienste
Schwangerschaftszeitraum: Pränatal, ≥20 Wochen Gestation, ≤20 Wochen Gestation, postpartal
Testverfahren: ABO-Typisierung, Rh-Typisierung mit Weak D, Antikörpersuchtest, Fetalscreen Rosette-Test, Flow Cytometry Hemoglobin F, Kleihauer Betke Fetal Stain
Dosierung: 300 Mikrogramm Rh Immune Globulin pro Standarddosis
Berechnungsgrundlage: Prozent fetaler Zellen × 50, Division durch 30 ml Vollblut pro Dosis
Indikation: Exposition gegenüber Rh positiven Erythrozyten
Besondere Hinweise: Fetalscreen nur gültig bei >20 Wochen und DAT negativem Neugeborenen
Topics: CMS-10518 0938-1246 Globulin